MARKET

FOLD

FOLD

Amicus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.61
+0.75
+8.47%
Closed 17:27 04/02 EDT
OPEN
8.73
PREV CLOSE
8.86
HIGH
9.62
LOW
8.73
VOLUME
2.60M
TURNOVER
--
52 WEEK HIGH
14.62
52 WEEK LOW
6.25
MARKET CAP
2.47B
P/E (TTM)
-6.3516
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FOLD stock price target is 18.13 with a high estimate of 31.00 and a low estimate of 10.00.

EPS

FOLD News

More
  • Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?
  • Zacks · 1d ago
  • XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
  • Seeking Alpha - Article · 2d ago
  • 3 Covid-19 Proof Biotech Stocks
  • Seeking Alpha - Article · 4d ago
  • Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. (FOLD)
  • Insider Monkey · 5d ago

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
More

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.